The Dow Jones index closed lower by over 80 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Earth Science Tech

• The Trade: Earth Science Tech, Inc. (OTC:ETST) Director Yovan Arturo Sanchez bought a total of 10,500 shares at an average price of $0.10. To acquire these shares, it cost around $1,050.
• What's Happening: On Jan. 29, Earth Science Tech announced a $5 million common stock repurchase program.
• What Earth Science Tech Does: Earth Science Tech Inc is a diversified holding company. Currently, the company is focused on emerging prospects in the health and wellness industry.

Nanophase Technologies

• The Trade: Nanophase Technologies Corporation (OTC:NANX) Director R Janet Whitmore acquired a total of 5,300 shares at an average price of $1.40. To acquire these shares, it cost around $7,420.
• What's Happening: On April 23, Nanophase Technologies announced financial results for the first quarter ended March 31, 2024.
• What Nanophase Technologies Does: Nanophase Technologies Corp is engaged in the production of engineered nanomaterial solutions and larger, sub-micron, materials such as personal care sunscreens, architectural coatings, industrial coating applications, and abrasion-resistant additives, plastics additives, medical diagnostics, energy.

Cerus

• The Trade: Cerus Corporation (NASDAQ:CERS) Director Jami K Nachtsheim acquired a total of 2,000 shares at an average price of $1.79. The insider spent around $3,578 to buy those shares.
• What's Happening: On May 2, Cerus said product revenue during the first quarter of 2024 was $38.4 million, up from $31.0 million in the year-ago period.
• What Cerus Does: Cerus Corp is a biomedical products company focused on the field of blood transfusion safety.

Zomedica

• The Trade: Zomedica Corp. (NYSE:ZOM) CEO Larry C Heaton II acquired a total of 100,000 shares at an average price of $0.14. The insider spent around $14,200 to buy those shares.
• What's Happening: On May 9, Zomedica reported a year-over-year decease in first-quarter GAAP EPS results and issued worse-than-expected quarterly sales results.
• What Zomedica Does: Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians.

Read This: Home Depot, Paysafe And 3 Stocks To Watch Heading Into Tuesday